Do analysts prefer SMMT or GMTX?

Summit Therapeutics currently has a consensus price target of $27.23, suggesting a potential upside of 94.33%. Given Summit Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Summit Therapeutics is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Summit Therapeutics 2 Sell rating(s) 6 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.47 Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings & valuation, SMMT or GMTX?

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Summit Therapeutics N/A N/A -$1.08B -$1.60 N/A Gemini Therapeutics N/A N/A -$71.87M -$1.00 N/A

Is SMMT or GMTX more profitable?

Gemini Therapeutics' return on equity of -38.78% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Summit Therapeutics N/A -291.24% -243.07% Gemini Therapeutics N/A -38.78% -35.88%

Do analysts prefer GMTX or RGC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, GMTX or RGC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gemini Therapeutics N/A N/A -$71.87M -$1.00 N/A Regencell Bioscience N/A N/A -$3.58M N/A N/A

Is GMTX or RGC more profitable?

Regencell Bioscience's return on equity of 0.00% beat Gemini Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gemini Therapeutics N/A -38.78% -35.88% Regencell Bioscience N/A N/A N/A

Do analysts rate AXSM or GMTX?

Axsome Therapeutics currently has a consensus price target of $256.79, suggesting a potential upside of 0.63%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Axsome Therapeutics is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Axsome Therapeutics 1 Sell rating(s) 0 Hold rating(s) 19 Buy rating(s) 1 Strong Buy rating(s) 2.95 Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend RDY or GMTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Gemini Therapeutics (GMTX) Competitors

$68.08 +0.83 (+1.23%)

As of 06/11/2026

Compare

GMTX vs. SMMT, RGC, AXSM, RDY, and ARWR

Should you buy Gemini Therapeutics stock or one of its competitors? MarketBeat compares Gemini Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Gemini Therapeutics include Summit Therapeutics (SMMT), Regencell Bioscience (RGC), Axsome Therapeutics (AXSM), Dr. Reddy's Laboratories (RDY), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry.

How does Gemini Therapeutics compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

Summit Therapeutics has a beta of -1.32, meaning that its stock price is 232% less volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the broader market.

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Summit Therapeutics currently has a consensus price target of $27.23, suggesting a potential upside of 94.33%. Given Summit Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Summit Therapeutics is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.47
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Summit Therapeutics had 13 more articles in the media than Gemini Therapeutics. MarketBeat recorded 13 mentions for Summit Therapeutics and 0 mentions for Gemini Therapeutics. Summit Therapeutics' average media sentiment score of 0.63 beat Gemini Therapeutics' score of 0.00 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Summit Therapeutics	Positive
Gemini Therapeutics	Neutral

4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are held by institutional investors. 83.5% of Summit Therapeutics shares are held by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Gemini Therapeutics' return on equity of -38.78% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
Gemini Therapeutics	N/A	-38.78%	-35.88%

Summary

Summit Therapeutics beats Gemini Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Gemini Therapeutics compare to Regencell Bioscience?

Gemini Therapeutics (NASDAQ:GMTX) and Regencell Bioscience (NASDAQ:RGC) are both mid-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Gemini Therapeutics has a beta of -0.12, suggesting that its share price is 112% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.65, suggesting that its share price is 65% more volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

In the previous week, Regencell Bioscience had 20 more articles in the media than Gemini Therapeutics. MarketBeat recorded 20 mentions for Regencell Bioscience and 0 mentions for Gemini Therapeutics. Regencell Bioscience's average media sentiment score of 0.09 beat Gemini Therapeutics' score of 0.00 indicating that Regencell Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Regencell Bioscience	Neutral

Regencell Bioscience's return on equity of 0.00% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Regencell Bioscience	N/A	N/A	N/A

75.4% of Gemini Therapeutics shares are held by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by company insiders. Comparatively, 2.0% of Regencell Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Regencell Bioscience beats Gemini Therapeutics on 7 of the 9 factors compared between the two stocks.

How does Gemini Therapeutics compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

In the previous week, Axsome Therapeutics had 22 more articles in the media than Gemini Therapeutics. MarketBeat recorded 22 mentions for Axsome Therapeutics and 0 mentions for Gemini Therapeutics. Axsome Therapeutics' average media sentiment score of 0.43 beat Gemini Therapeutics' score of 0.00 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Axsome Therapeutics	Neutral
Gemini Therapeutics	Neutral

Gemini Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Gemini Therapeutics' return on equity of -38.78% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Gemini Therapeutics	N/A	-38.78%	-35.88%

Axsome Therapeutics has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, suggesting that its stock price is 112% less volatile than the broader market.

Gemini Therapeutics has lower revenue, but higher earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Gemini Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	20.57	-$183.17M	-$3.73	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Axsome Therapeutics currently has a consensus price target of $256.79, suggesting a potential upside of 0.63%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Axsome Therapeutics is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Axsome Therapeutics beats Gemini Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Gemini Therapeutics compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Dr. Reddy's Laboratories has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, indicating that its stock price is 112% less volatile than the broader market.

In the previous week, Dr. Reddy's Laboratories' average media sentiment score of 0.00 equaled Gemini Therapeutics'average media sentiment score.

Company	Overall Sentiment
Dr. Reddy's Laboratories	Neutral
Gemini Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Dr. Reddy's Laboratories has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$335.93B	0.03	$456M	$0.58	22.94
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Gemini Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 12.34% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%
Gemini Therapeutics	N/A	-38.78%	-35.88%

3.8% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Dr. Reddy's Laboratories beats Gemini Therapeutics on 9 of the 11 factors compared between the two stocks.

How does Gemini Therapeutics compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

Gemini Therapeutics has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Gemini Therapeutics' return on equity of -38.78% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%
Gemini Therapeutics	N/A	-38.78%	-35.88%

Arrowhead Pharmaceuticals has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$622.01M	16.88	-$1.63M	-$2.15	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Arrowhead Pharmaceuticals has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, indicating that its stock price is 112% less volatile than the broader market.

Arrowhead Pharmaceuticals presently has a consensus target price of $87.80, indicating a potential upside of 17.82%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Arrowhead Pharmaceuticals had 5 more articles in the media than Gemini Therapeutics. MarketBeat recorded 5 mentions for Arrowhead Pharmaceuticals and 0 mentions for Gemini Therapeutics. Arrowhead Pharmaceuticals' average media sentiment score of 1.51 beat Gemini Therapeutics' score of 0.00 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Arrowhead Pharmaceuticals	Very Positive
Gemini Therapeutics	Neutral

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Arrowhead Pharmaceuticals beats Gemini Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Gemini Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GMTX vs. The Competition

Export

Metric	Gemini Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.95B	$985.83M	$6.50B	$11.97B
Dividend Yield	N/A	4.84%	2.67%	5.57%
P/E Ratio	-68.08	1.46	23.86	24.47
Price / Sales	N/A	120.60	535.07	122.57
Price / Cash	N/A	20.06	43.20	54.62
Price / Book	23.56	7.86	10.66	6.81
Net Income	-$71.87M	-$4.88M	$3.56B	$337.76M
7 Day Performance	-4.26%	0.75%	0.16%	2.19%
1 Month Performance	-1.66%	4.44%	0.44%	3.23%
1 Year Performance	33.86%	101.73%	22.85%	27.91%

Gemini Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GMTX Gemini Therapeutics	N/A	$68.08 +1.2%	N/A	+26.7%	$2.95B	N/A	N/A	30
SMMT Summit Therapeutics	3.5907 of 5 stars	$15.07 +1.4%	$26.05 +72.9%	-33.2%	$11.53B	N/A	N/A	110	Insider Trade
RGC Regencell Bioscience	0.314 of 5 stars	$23.75 +2.6%	N/A	N/A	$11.45B	N/A	N/A	10
AXSM Axsome Therapeutics	1.783 of 5 stars	$233.31 +5.0%	$251.26 +7.7%	+134.8%	$11.43B	$638.50M	N/A	380	News Coverage Analyst Upgrade Insider Trade
RDY Dr. Reddy's Laboratories	1.3513 of 5 stars	$13.06 +0.2%	$16.90 +29.5%	-16.1%	$10.88B	$3.58B	22.51	27,811

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GMTX) was last updated on 6/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gemini Therapeutics (GMTX) Competitors

GMTX vs. SMMT, RGC, AXSM, RDY, and ARWR

How does Gemini Therapeutics compare to Summit Therapeutics?

Summary

How does Gemini Therapeutics compare to Regencell Bioscience?

Summary

How does Gemini Therapeutics compare to Axsome Therapeutics?

Summary

How does Gemini Therapeutics compare to Dr. Reddy's Laboratories?

Summary

How does Gemini Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMTX vs. The Competition

Gemini Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gemini Therapeutics (GMTX) Competitors

GMTX vs. SMMT, RGC, AXSM, RDY, and ARWR

How does Gemini Therapeutics compare to Summit Therapeutics?

Which has more risk and volatility, SMMT or GMTX?

Which has higher earnings & valuation, SMMT or GMTX?

Do analysts prefer SMMT or GMTX?

Does the media refer more to SMMT or GMTX?

Do institutionals & insiders have more ownership in SMMT or GMTX?

Is SMMT or GMTX more profitable?

Summary

How does Gemini Therapeutics compare to Regencell Bioscience?

Which has more volatility and risk, GMTX or RGC?

Which has better earnings and valuation, GMTX or RGC?

Does the media favor GMTX or RGC?

Is GMTX or RGC more profitable?

Do insiders & institutionals hold more shares of GMTX or RGC?

Do analysts prefer GMTX or RGC?

Summary

How does Gemini Therapeutics compare to Axsome Therapeutics?

Does the media favor AXSM or GMTX?

Is AXSM or GMTX more profitable?

Which has more risk and volatility, AXSM or GMTX?

Which has better valuation & earnings, AXSM or GMTX?

Do insiders and institutionals hold more shares of AXSM or GMTX?

Do analysts rate AXSM or GMTX?

Summary

How does Gemini Therapeutics compare to Dr. Reddy's Laboratories?

Which has more volatility & risk, RDY or GMTX?

Does the media prefer RDY or GMTX?

Do analysts recommend RDY or GMTX?

Which has better earnings & valuation, RDY or GMTX?

Is RDY or GMTX more profitable?

Do insiders & institutionals believe in RDY or GMTX?

Summary

How does Gemini Therapeutics compare to Arrowhead Pharmaceuticals?

Is ARWR or GMTX more profitable?

Which has preferable valuation and earnings, ARWR or GMTX?

Which has more risk & volatility, ARWR or GMTX?

Do analysts prefer ARWR or GMTX?

Does the media prefer ARWR or GMTX?

Do insiders and institutionals believe in ARWR or GMTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMTX vs. The Competition

Gemini Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools